Claritev Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CTEV research report →
Range $30 – $73
Price Chart
About the company
Claritev Corporation, together with its affiliated companies, provides advanced data analytics and technology-enabled services focused on cost management, payment optimization, and revenue assurance for the healthcare sector across the United States. The company offers a suite of services designed to reduce medical expenses. This includes analytics-driven solutions that utilize sophisticated algorithms and data insights to pinpoint billing overcharges, subsequently assisting with or recommending appropriate reimbursement negotiations.
- CEO
- Travis S. Dalton
- IPO
- 2020
- Employees
- 3,000
- HQ
- McLean, VA, US
Get TickerSpark's AI analysis on CTEV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $580.99M
- P/E
- -2.00
- PEG
- -0.03
- P/S
- 0.58
- P/B
- -1.96
- EV/EBITDA
- 8.79
- Div Yield
- 0.00%
- Gross Margin
- 44.27%
- Op Margin
- 4.91%
- Net Margin
- -28.46%
- ROE
- 139.56%
- ROIC
- 0.94%
Latest fiscal year · YoY change
- Revenue
- $965.41M+3.7%
- Gross Profit
- $266.58M-61.4%
- Op Income
- $45.06M
- Net Income
- $-284,282,000+82.7%
- EPS
- $-17.30+83.0%
- OCF Growth
- +9.0%
- FCF Growth
- -16.8%
- 52W High
- $74.07
- 52W Low
- $11.50
- 50D MA
- $30.22
- 200D MA
- $29.43
- Beta
- 0.79
- RSI (14)
- 56
- Avg Volume
- 121.22K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Claritev posted a strong Q2 with revenue, EBITDA and cash flow all beating expectations, raised full-year guidance, and said its bookings and AI-enabled transformation are building momentum.· August 7, 2026
- Q2 revenue was $257.5 million, up 6.6% year over year, with adjusted EBITDA of $155.8 million and a 60.5% margin.
- Cash generation was strong: operating cash flow was $93 million, unlevered free cash flow was $89.5 million, and levered free cash flow was $54.6 million.
- Bookings were a highlight, with $74 million of ACV in the first half and management saying full-year bookings should exceed $100 million.
- Management raised 2026 revenue guidance to $1.0 billion-$1.02 billion, adjusted EBITDA to $610 million-$620 million, and free cash flow to $5 million-$15 million.
- Growth was driven by Claims Intelligence, especially NSA-related volume, while TPA and Medicare Advantage were called out as important newer growth areas.
Total revenue was $257.5 million in Q2, up 6.6% year over year. Adjusted EBITDA was $155.8 million, or 60.5% of revenue. The company said Claims Intelligence was up close to 14%, PSAV revenue was $220 million, and revenue growth excluding a prior-year one-time item would have been nearly 9%. Cash flow was also strong, with $93 million of operating cash flow, $89.5 million of unlevered free cash flow, and $54.6 million of levered free cash flow. For 2026, Claritev raised revenue guidance to $1 billion-$1.02 billion, adjusted EBITDA to $610 million-$620 million, and free cash flow to $5 million-$15 million; it kept capital spend guidance at $160 million-$170 million. Management also said Q3 revenue should be modeled flat sequentially, and that full-year ACV bookings growth should be at least 50% with bookings above $100 million for the year.
Travis Dalton framed the quarter as evidence that Claritev's turnaround is working and said the company is entering a “year of the way up” with sustainable growth returning. He emphasized that the strategy of building horizontal solutions across vertical markets is gaining traction, supported by investments in technology modernization, data architecture and talent. Dalton repeatedly linked the company's future to AI, saying Claritev's organized data and cloud-based workflows position it to deploy AI responsibly at scale and improve client outcomes.
Doug Garis said the quarter exceeded internal expectations on revenue, EBITDA, cash flow and bookings, and highlighted that Q2 was the company's strongest revenue quarter in 15 quarters and strongest EBITDA quarter in 13 quarters. He pointed to $93 million of operating cash flow, $89.5 million of unlevered free cash flow and $54.6 million of levered free cash flow, with DPO and DSO improving by more than 5 days. Garis also said bookings conversion was running ahead of expectations, that active pipeline was above $300 million, and that the company is raising 2026 revenue, EBITDA and free cash flow guidance while keeping capital spend unchanged.
Analysts focused on whether the NSA-related volume strength was a one-quarter bump or something more durable, and Garis said the company sees a healthy environment into the second half but is modeling conservatively because the impact of new NSA rules is still hard to isolate. Questions also centered on the timing of bookings converting to revenue; management reiterated the usual 2-4 quarter ramp to first revenue and about 4 quarters to annualize, while noting some larger NSA and payer wins turned on earlier than expected. Analysts asked about the mix of revenue by segment and AI-led savings, and management said Claims Intelligence was the main upside driver, Payment and Revenue Integrity is trending toward growth, and AI initiatives like ProPricer have identified over $1 billion of additional savings.
The call showed clear operating momentum: revenue, EBITDA, cash flow and bookings all beat, and management raised full-year guidance across the board. Bookings were broad-based, pipeline topped $300 million, and leadership said growth is coming from both core clients and new verticals like TPA, public sector and Medicare Advantage. Management also sounded confident that AI, digital modernization and NSA expertise can support both growth and operating leverage.
Management still described the business as dependent on claims volume timing and NSA rule implementation, which they said could stay hard to read in the second half. Revenue mix remains affected by one-time items and product shifts, and Garis said Q3 should be modeled flat sequentially with Q4 potentially lower depending on volume flow-through. They also said they will keep investing heavily in sales, marketing and operations, so near-term margins and cash flow must absorb that growth investment.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 42.7%
- Shares Outstanding
- 17.05M
- Float Shares
- 7.28M
of shares held by institutions
110 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 584.47K | ▲ 66.70K |
| Kent Lake Pr LLC | 35.00K | ▼ 65.00K |
| Cubist Systematic Strategies, LLC | 27.37K | ▲ 27.37K |
| Axa Investment Managers S.A. | 21.24K | ▲ 21.24K |
| Quest Partners LLC | 3.99K | ▼ 3.99K |
| Cwm, LLC | 1.69K | ▲ 1.66K |
| California State Teachers Retirement System | 490 | ▼ 5.13K |
| Point72 Europe (London) Llp | 212 | ▲ 212 |
| Point72 (Difc) Ltd | 210 | ▲ 210 |
Held by 106 ETFs
Biggest fund positions in CTEV by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 14, 26 | Misencik Tiffani | sell | 8,850 |
| Aug 10, 26 | Mintz William B. | sell | 8,431 |
| Aug 5, 26 | Mintz William B. | other | 3,622 |
| Aug 5, 26 | Garis Douglas Michael | other | 11,711 |
| Jun 30, 26 | Albinson Brock | other | 3,649 |
| Jun 9, 26 | Carol Nutter | buy | 875 |
| May 18, 26 | Kim Michael | buy | 3,000 |
| May 19, 26 | Prince John Michael | buy | 10,000 |
| May 18, 26 | Dalton Travis | buy | 11,200 |
| May 18, 26 | Dalton Travis | buy | 9,720 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CTEV coverage
Recent articles, reports, and earnings notes.
No research on CTEV yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CTEV report →Marpai Expands Relationship with Claritev to Help Reduce Healthcare Costs for Employer Clients
businesswire.com · Aug 17
Claritev Analysts Raise Their Forecasts Following Q2 Earnings
benzinga.com · Aug 10
Claritev Q2 Earnings Call Highlights
marketbeat.com · Aug 7
Claritev Corporation (CTEV) Q2 2026 Earnings Call Transcript
seekingalpha.com · Aug 7
Claritev Corporation (CTEV) Reports Q2 Loss, Tops Revenue Estimates
zacks.com · Aug 7
Claritev Corporation Reports Second Quarter 2026 Results
businesswire.com · Aug 7
Claritev Corporation Announces Participation in Canaccord Genuity 46th Annual Growth Conference
gurufocus.com · Aug 4
Claritev Corporation Announces Participation in Canaccord Genuity 46th Annual Growth Conference
businesswire.com · Aug 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.